Last reviewed · How we verify
NCT04516135
Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers
Phase 2 trial testing 3-Dimensional Conformal Radiation Therapy in Metastatic Malignant Female Reproductive System Neoplasm in 28 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2029
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 11 January 2021 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2029 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- 3-Dimensional Conformal Radiation Therapy
- Intensity-Modulated Radiation Therapy
- Quality-of-Life Assessment
- Questionnaire Administration
- Volume Modulated Arc Therapy
Conditions studied
- Metastatic Malignant Female Reproductive System Neoplasm — all drugs for Metastatic Malignant Female Reproductive System Neoplasm →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, female only, with Metastatic Malignant Female Reproductive System Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies if a single session of palliative radiation therapy can help improve symptoms of gynecologic cancers that have spread to other places in the body (metastatic) and that affect quality of life as well or more so than multiple sessions (which is the standard of care). Palliative radiation therapy may help patients with metastatic gynecologic cancers live more comfortably. Researchers also want to learn how radiation affects the immune system and to compare the effects of giving one radiation treatment to giving multiple radiation treatments.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis.
Sevcikova A, Mladosievicova B, Mego M, Ciernikova S. · · 2023 · cited 17× · PMID 38139030 · DOI 10.3390/ijms242417199
Verify or expand the search:
- PubMed search for NCT04516135
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 3-Dimensional Conformal Radiation Therapy
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT06368817 — A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma · Phase 2 · recruiting
- NCT04397679 — Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma · Phase 1 · terminated
- NCT04546399 — A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acu · Phase 2 · recruiting
- NCT04423211 — Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging · Phase 3 · recruiting
Other recruiting trials for Metastatic Malignant Female Reproductive System Neoplasm
Currently open trials in the same condition.
- NCT05092373 — Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i · Phase 1 · recruiting
- NCT04819997 — A Nurse-Led Intervention for Fear of Progression in Advanced Cancer · NA · active not recruiting
- NCT04395079 — Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurre · Phase 2 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04516135 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04516135.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing